ABSTRACT
DISEASE OVERVIEW: Ring sideroblasts (RS) are erythroid precursors with abnormal perinuclear mitochondrial iron accumulation. Two myeloid neoplasms defined by the presence of RS, include refractory anemia with ring sideroblasts (RARS), now classified under myelodysplastic syndromes with RS (MDS-RS) and RARS with thrombocytosis (RARS-T); now called myelodysplastic/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN-RS-T). DIAGNOSIS: MDS-RS is a lower-risk MDS, with single or multilineage dysplasia (SLD/MLD), <5% bone marrow (BM) blasts and ≥ 15% BM RS (≥5% in the presence of SF3B1 mutations). MDS/MPN-RS-T, now a formal entity in the MDS/MPN overlap syndromes, has diagnostic features of MDS-RS-SLD, along with a platelet count ≥450 × 10(9)/L and large atypical megakaryocytes. MUTATIONS AND KARYOTYPE: Mutations in SF3B1 are seen in ≥80% of patients with MDS-RS-SLD and MDS/MPN-RS-T, and strongly correlate with the presence of BM RS; MDS/MPN-RS-T patients also demonstrate JAK2V617F, ASXL1, DNMT3A, SETBP1, and TET2 mutations. Cytogenetic abnormalities are uncommon in both. RISK STRATIFICATION: Most patients with MDS-RS-SLD are stratified into lower-risk groups by the revised-IPSS. Disease outcome in MDS/MPN-RS-T is better than that of MDS-RS-SLD, but worse than that of essential thrombocythemia. Both diseases have a low risk of leukemic transformation. TREATMENT: Anemia and iron overload are complications seen in both and are managed similar to lower-risk MDS and MPN. The advent of luspatercept, a first-in-class erythroid maturation agent will tremendously boost the ability to manage anemia. Aspirin therapy is reasonable in MDS/MPN-RS-T, especially in the presence of JAK2V617F, but the value of platelet-lowering drugs remains uncertain.
Subject(s)
Anemia, Refractory , Mutation , Anemia, Refractory/blood , Anemia, Refractory/diagnosis , Anemia, Refractory/genetics , Anemia, Refractory/therapy , Anemia, Sideroblastic/blood , Anemia, Sideroblastic/diagnosis , Anemia, Sideroblastic/genetics , Anemia, Sideroblastic/therapy , Erythroblasts/metabolism , Female , Humans , Iron Overload/blood , Iron Overload/diagnosis , Iron Overload/genetics , Iron Overload/therapy , Male , Myelodysplastic-Myeloproliferative Diseases , Thrombocytosis/blood , Thrombocytosis/diagnosis , Thrombocytosis/genetics , Thrombocytosis/therapyABSTRACT
Although azacitidine is the first-line drug for higher-risk myelodysplastic syndrome (MDS) patients, its efficacy for lower-risk MDS remains unestablished. Therefore, we conducted a prospective study to examine the efficacy and safety of a 5-day regimen of azacitidine (AZA-5) for lower-risk MDS. The primary endpoint was hematological improvement (HI) after 4 courses of therapy. A total of 51 patients with lower-risk MDS based on the French-American-British (FAB) classification (44 patients with refractory anemia [RA] and 7 patients with refractory anemia with ringed sideroblasts [RARS]) were enrolled from 6 centers in Japan. The median age was 75 years (range: 51-88). These patients received AZA-5 (75 mg/m2 ; once daily for 5 sequential days). The median number of AZA-5 courses was 8 (range: 1-57), and 45 patients (88.2%) received more than 4 courses. HI and transfusion independency were seen in 24 patients (47.1%) and 11 patients (39.2%), respectively. A total of 11 patients (21.6%) achieved complete remission or marrow remission. WT1 mRNA levels were not significantly correlated with therapy response. Grade 3 or 4 neutropenia and thrombocytopenia occurred in 26 (51.0%) and 11 (21.5%) patients, respectively. Nonhematological grade 3 or 4 adverse events were observed in 9 patients (17.6%). Together, these results indicate that AZA-5 is feasible and effective for lower-risk MDS patients as well as for higher-risk MDS patients.
Subject(s)
Anemia, Refractory/drug therapy , Anemia, Sideroblastic/drug therapy , Antimetabolites, Antineoplastic/therapeutic use , Azacitidine/therapeutic use , Aged , Aged, 80 and over , Anemia, Refractory/blood , Anemia, Sideroblastic/blood , Blood Component Transfusion/statistics & numerical data , Drug Administration Schedule , Feasibility Studies , Febrile Neutropenia/chemically induced , Febrile Neutropenia/epidemiology , Female , Humans , Japan/epidemiology , Male , Middle Aged , Prospective Studies , Thrombocytopenia/chemically induced , Thrombocytopenia/epidemiology , Treatment OutcomeSubject(s)
Anemia, Sideroblastic/complications , Anemia, Sideroblastic/drug therapy , Anti-Bacterial Agents/adverse effects , Antitubercular Agents/therapeutic use , Ethambutol/therapeutic use , Linezolid/adverse effects , Seizures/etiology , Tuberculosis, Multidrug-Resistant , Anemia, Sideroblastic/blood , Anemia, Sideroblastic/etiology , Fatigue/etiology , Hemoglobins , Humans , Magnetic Resonance Imaging , Male , Middle Aged , Tuberculosis, Multidrug-Resistant/complications , Tuberculosis, Multidrug-Resistant/drug therapyABSTRACT
OBJECTIVES: To characterise the clinical features, immune manifestations and molecular mechanisms in a recently described autoinflammatory disease caused by mutations in TRNT1, a tRNA processing enzyme, and to explore the use of cytokine inhibitors in suppressing the inflammatory phenotype. METHODS: We studied nine patients with biallelic mutations in TRNT1 and the syndrome of congenital sideroblastic anaemia with immunodeficiency, fevers and developmental delay (SIFD). Genetic studies included whole exome sequencing (WES) and candidate gene screening. Patients' primary cells were used for deep RNA and tRNA sequencing, cytokine profiling, immunophenotyping, immunoblotting and electron microscopy (EM). RESULTS: We identified eight mutations in these nine patients, three of which have not been previously associated with SIFD. Three patients died in early childhood. Inflammatory cytokines, mainly interleukin (IL)-6, interferon gamma (IFN-γ) and IFN-induced cytokines were elevated in the serum, whereas tumour necrosis factor (TNF) and IL-1ß were present in tissue biopsies of patients with active inflammatory disease. Deep tRNA sequencing of patients' fibroblasts showed significant deficiency of mature cytosolic tRNAs. EM of bone marrow and skin biopsy samples revealed striking abnormalities across all cell types and a mix of necrotic and normal-appearing cells. By immunoprecipitation, we found evidence for dysregulation in protein clearance pathways. In 4/4 patients, treatment with a TNF inhibitor suppressed inflammation, reduced the need for blood transfusions and improved growth. CONCLUSIONS: Mutations of TRNT1 lead to a severe and often fatal syndrome, linking protein homeostasis and autoinflammation. Molecular diagnosis in early life will be crucial for initiating anti-TNF therapy, which might prevent some of the severe disease consequences.
Subject(s)
Anemia, Sideroblastic/genetics , Anti-Inflammatory Agents/therapeutic use , Genetic Diseases, X-Linked/genetics , Immunologic Deficiency Syndromes/genetics , Mutation , Nucleotidyltransferases/genetics , RNA, Transfer/genetics , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Adult , Anemia, Sideroblastic/blood , Child , Child, Preschool , Cytokines/blood , Cytokines/genetics , Developmental Disabilities/genetics , Female , Genetic Diseases, X-Linked/blood , Humans , Immunophenotyping , Male , Pedigree , Phenotype , Tumor Necrosis Factor-alpha/analysis , Exome SequencingABSTRACT
Refractory anaemia with ring sideroblasts (RARS) is distinguished by hyperplastic inefficient erythropoiesis, aberrant mitochondrial ferritin accumulation and anaemia. Heterozygous mutations in the spliceosome gene SF3B1 are found in a majority of RARS cases. To explore the link between SF3B1 mutations and anaemia, we studied mutated RARS CD34(+) marrow cells with regard to transcriptome sequencing, splice patterns and mutational allele burden during erythroid differentiation. Transcriptome profiling during early erythroid differentiation revealed a marked up-regulation of genes involved in haemoglobin synthesis and in the oxidative phosphorylation process, and down-regulation of mitochondrial ABC transporters compared to normal bone marrow. Moreover, mis-splicing of genes involved in transcription regulation, particularly haemoglobin synthesis, was confirmed, indicating a compromised haemoglobinization during RARS erythropoiesis. In order to define the phase during which erythroid maturation of SF3B1 mutated cells is most affected, we assessed allele burden during erythroid differentiation in vitro and in vivo and found that SF3B1 mutated erythroblasts showed stable expansion until late erythroblast stage but that terminal maturation to reticulocytes was significantly reduced. In conclusion, SF3B1 mutated RARS progenitors display impaired splicing with potential downstream consequences for genes of key importance for haemoglobin synthesis and terminal erythroid differentiation.
Subject(s)
Anemia, Refractory/genetics , Anemia, Sideroblastic/genetics , Erythropoiesis/genetics , Hemoglobins/biosynthesis , Phosphoproteins/genetics , RNA Splicing/genetics , Ribonucleoprotein, U2 Small Nuclear/genetics , Aged , Aged, 80 and over , Anemia, Refractory/blood , Anemia, Sideroblastic/blood , Biological Transport/genetics , Gene Expression Profiling , Genes, Tumor Suppressor , Genetic Heterogeneity , Humans , Iron/metabolism , Phosphoproteins/physiology , Protein Isoforms/genetics , RNA Splicing Factors , RNA, Messenger/genetics , Ribonucleoprotein, U2 Small Nuclear/physiology , Sequence Analysis, RNA , Signal Transduction/geneticsABSTRACT
Congenital sideroblastic anemias (CSAs) are a heterogeneous group of inherited disorders identified by pathological erythroid precursors with perinuclear mitochondrial iron deposition in bone marrow. An international collaborative group of physicians and laboratory scientists collated clinical information on cases of CSA lacking known causative mutations, identifying a clinical subgroup of CSA associated with B immunodeficiency, periodic fevers, and development delay. Twelve cases from 10 families were identified. Median age at presentation was 2 months. Anemia at diagnosis was sideroblastic, typically severe (median hemoglobin, 7.1 g/dL) and markedly microcytic (median mean corpuscular volume, 62.0 fL). Clinical course involved recurrent febrile illness and gastrointestinal disturbance, lacking an infective cause. Investigation revealed B-cell lymphopenia (CD19⺠range, 0.016-0.22 × 109/L) and panhypogammaglobulinemia in most cases. Children displayed developmental delay alongside variable neurodegeneration, seizures, cerebellar abnormalities, sensorineural deafness, and other multisystem features. Most required regular blood transfusion, iron chelation, and intravenous immunoglobulin replacement. Median survival was 48 months, with 7 deaths caused by cardiac or multiorgan failure. One child underwent bone marrow transplantation aged 9 months, with apparent cure of the hematologic and immunologic manifestations. We describe and define a novel CSA and B-cell immunodeficiency syndrome with additional features resembling a mitochondrial cytopathy. The molecular etiology is under investigation.
Subject(s)
Anemia, Sideroblastic/diagnosis , B-Lymphocytes/immunology , Developmental Disabilities/diagnosis , Familial Mediterranean Fever/diagnosis , Immunologic Deficiency Syndromes/diagnosis , Anemia, Sideroblastic/blood , Anemia, Sideroblastic/genetics , Developmental Disabilities/blood , Developmental Disabilities/genetics , Familial Mediterranean Fever/blood , Familial Mediterranean Fever/genetics , Female , Hearing Loss, Sensorineural/blood , Hearing Loss, Sensorineural/diagnosis , Hearing Loss, Sensorineural/genetics , Humans , Immunologic Deficiency Syndromes/blood , Immunologic Deficiency Syndromes/genetics , Infant , Infant, Newborn , Male , Nervous System Diseases/blood , Nervous System Diseases/diagnosis , Nervous System Diseases/genetics , Pedigree , Phenotype , SyndromeSubject(s)
Janus Kinase 2/genetics , Mutation , Myelodysplastic-Myeloproliferative Diseases/blood , Myelodysplastic-Myeloproliferative Diseases/genetics , Phosphoproteins/genetics , RNA Splicing Factors/genetics , Aged , Anemia, Sideroblastic/blood , Anemia, Sideroblastic/genetics , Erythroblasts/pathology , Female , Humans , Thrombocytosis/blood , Thrombocytosis/geneticsABSTRACT
X-linked sideroblastic anemia (XLSA) is the most common form of congenital sideroblastic anemia. In affected males, it is uniformly associated with partial loss-of-function missense mutations in the erythroid-specific heme biosynthesis protein 5-aminolevulinate synthase 2 (ALAS2). Here, we report five families with XLSA owing to mutations in a GATA transcription factor binding site located in a transcriptional enhancer element in intron 1 of the ALAS2 gene. As such, this study defines a new class of mutations that should be evaluated in patients undergoing genetic testing for a suspected diagnosis of XLSA.
Subject(s)
5-Aminolevulinate Synthetase/genetics , Anemia, Sideroblastic/genetics , Enhancer Elements, Genetic/genetics , GATA Transcription Factors/metabolism , Genetic Diseases, X-Linked/genetics , Introns/genetics , Mutation , Adult , Aged , Anemia, Sideroblastic/blood , Binding Sites , Europe/ethnology , Female , Genetic Diseases, X-Linked/blood , Genotype , Humans , Male , Middle Aged , Pedigree , Young AdultABSTRACT
Sideroblastic anemia is characterized by anemia with the emergence of ring sideroblasts in the bone marrow. There are two forms of sideroblastic anemia, i.e., congenital sideroblastic anemia (CSA) and acquired sideroblastic anemia. In order to clarify the pathophysiology of sideroblastic anemia, a nationwide survey consisting of clinical and molecular genetic analysis was performed in Japan. As of January 31, 2012, data of 137 cases of sideroblastic anemia, including 72 cases of myelodysplastic syndrome (MDS)-refractory cytopenia with multilineage dysplasia (RCMD), 47 cases of MDS-refractory anemia with ring sideroblasts (RARS), and 18 cases of CSA, have been collected. Hemoglobin and MCV level in CSA are significantly lower than those of MDS, whereas serum iron level in CSA is significantly higher than those of MDS. Of 14 CSA for which DNA was available for genetic analysis, 10 cases were diagnosed as X-linked sideroblastic anemia due to ALAS2 gene mutation. The mutation of SF3B1 gene, which was frequently mutated in MDS-RS, was not detected in CSA patients. Together with the difference of clinical data, it is suggested that genetic background, which is responsible for the development of CSA, is different from that of MDS-RS.
Subject(s)
Anemia, Sideroblastic/congenital , 5-Aminolevulinate Synthetase/deficiency , 5-Aminolevulinate Synthetase/genetics , 5-Aminolevulinate Synthetase/metabolism , ATP-Binding Cassette Transporters/deficiency , ATP-Binding Cassette Transporters/genetics , Adolescent , Adult , Age of Onset , Aged , Anemia, Sideroblastic/blood , Anemia, Sideroblastic/classification , Anemia, Sideroblastic/epidemiology , Anemia, Sideroblastic/genetics , Child , Child, Preschool , Chromosome Aberrations , Female , Gene Frequency , Genes, X-Linked , Genetic Diseases, X-Linked/blood , Genetic Diseases, X-Linked/genetics , Glutaredoxins/deficiency , Glutaredoxins/genetics , Health Surveys , Humans , Hydro-Lyases/deficiency , Hydro-Lyases/genetics , Infant , Infant, Newborn , Japan/epidemiology , Male , Membrane Transport Proteins/deficiency , Membrane Transport Proteins/genetics , Middle Aged , Mitochondrial Membrane Transport Proteins/deficiency , Mitochondrial Membrane Transport Proteins/genetics , Myelodysplastic Syndromes/blood , Myelodysplastic Syndromes/drug therapy , Myelodysplastic Syndromes/epidemiology , Myelodysplastic Syndromes/genetics , Phosphoproteins/deficiency , Phosphoproteins/genetics , RNA Splicing Factors , Recombinant Fusion Proteins/metabolism , Ribonucleoprotein, U2 Small Nuclear/deficiency , Ribonucleoprotein, U2 Small Nuclear/genetics , Treatment Outcome , Vitamin B 6/therapeutic use , Young AdultABSTRACT
Pyridoxine, or vitamin B6, is commonly used to treat acquired idiopathic sideroblastic anaemia (AISA, including refractory anaemia with ring sideroblasts), but the efficacy of this therapy in an unselected AISA population (i.e. patients without confirmed ALAS2 or other pyridoxine-responsive germline mutations) has not been established. We reviewed clinical data from 231 patients with AISA and found that 42% of 203 evaluable patients had been treated with pyridoxine. Only 6.8% of pyridoxine-treated patients experienced a haemoglobin improvement (≥ 1.5 g/dL) meeting 2006 International Working Group for Myelodysplastic Syndromes standardised response criteria. As some patients received combination therapy with erythropoietin or other agents, improvement could be attributed to pyridoxine monotherapy in only one patient (1.4%). Smaller, less meaningful increments in haemoglobin levels of 0.5 g/dL were observed in 13.5% of patients. Response to therapy did not correlate with International Prognostic Scoring System (IPSS) risk group or multilineage vs unilineage dysplasia. New symptomatic peripheral neuropathy was noted in 2.3% of patients treated with pyridoxine. In this large series of unselected patients with sideroblastic anaemia, pyridoxine therapy was ineffective and was associated with a risk of adverse effects. Pyridoxine therapy should be reserved for patients with known or suspected pyridoxine-responsive mutations.
Subject(s)
Anemia, Refractory/drug therapy , Anemia, Sideroblastic/drug therapy , Pyridoxine/therapeutic use , 5-Aminolevulinate Synthetase/genetics , Adult , Aged , Aged, 80 and over , Anemia, Refractory/blood , Anemia, Refractory/genetics , Anemia, Sideroblastic/blood , Anemia, Sideroblastic/genetics , Female , Hemoglobins/metabolism , Humans , Male , Middle Aged , Mutation , Peripheral Nervous System Diseases/chemically induced , Prognosis , Pyridoxine/adverse effects , Retrospective Studies , Treatment Failure , Treatment OutcomeABSTRACT
Among the etiologies of anemia in the infancy, the mitochondrial cytopathies are infrequent. Pearson syndrome is diagnosed principally during the initial stages of life and it is characterized by refractory sideroblastic anemia with vacuolization of marrow progenitor cells, exocrine pancreatic dysfunction and variable neurologic, hepatic, renal and endocrine failures. We report the case of a 14 month-old girl evaluated by a multicentric study, with clinic and molecular diagnosis of Pearson syndrome, with the 4,977-base pair common deletion of mitochondrial DNA. This entity has been associated to diverse phenotypes within the broad clinical spectrum of mitochondrial disease.
Subject(s)
Anemia, Sideroblastic , Mitochondrial Diseases , Acyl-CoA Dehydrogenase, Long-Chain/deficiency , Anemia, Sideroblastic/blood , Anemia, Sideroblastic/diagnosis , Anemia, Sideroblastic/genetics , Congenital Bone Marrow Failure Syndromes , DNA, Mitochondrial/genetics , Diarrhea, Infantile/etiology , Exocrine Pancreatic Insufficiency/etiology , Exocrine Pancreatic Insufficiency/genetics , Fatal Outcome , Female , Humans , Hypokalemia/etiology , Infant , Lipid Metabolism, Inborn Errors , Mitochondrial Diseases/blood , Mitochondrial Diseases/diagnosis , Mitochondrial Diseases/genetics , Muscular Diseases , Phenotype , Referral and Consultation , Sequence Analysis, DNA , Sequence DeletionABSTRACT
Erythroferrone (ERFE), the erythroid regulator of iron metabolism, inhibits hepcidin to increase iron availability for erythropoiesis. ERFE plays a pathological role during ineffective erythropoiesis as occurs in X-linked sideroblastic anemia (XLSA) and ß-thalassemia. Its measurement might serve as an indicator of severity for these diseases. However, for reliable quantification of ERFE analytical characterization is indispensable to determine the assay's limitations and define proper methodology. We developed a sandwich ELISA for human serum ERFE using polyclonal antibodies and report its extensive analytical validation. This new assay showed, for the first time, the differentiation of XLSA and ß-thalassemia major patients from healthy controls (p = 0.03) and from each other (p<0.01), showing the assay provides biological plausible results. Despite poor dilution linearity, parallelism and recovery in patient serum matrix, which indicated presence of a matrix effect and/or different immunoreactivity of the antibodies to the recombinant standard and the endogenous analyte, our assay correlated well with two other existing ERFE ELISAs (both R2 = 0.83). Nevertheless, employment of one optimal dilution of all serum samples is warranted to obtain reliable results. When adequately performed, the assay can be used to further unravel the human erythropoiesis-hepcidin-iron axis in various disorders and assess the added diagnostic value of ERFE.
Subject(s)
Anemia, Sideroblastic/diagnosis , Peptide Hormones/analysis , beta-Thalassemia/diagnosis , Adult , Aged , Anemia/blood , Anemia/diagnosis , Anemia, Sideroblastic/blood , Cytokines/metabolism , Enzyme-Linked Immunosorbent Assay , Erythropoiesis , Female , Hepcidins/blood , Humans , Iron/metabolism , Iron Overload/diagnosis , Iron Overload/metabolism , Male , Middle Aged , Peptide Hormones/blood , beta-Thalassemia/bloodABSTRACT
OBJECTIVE: To assess the applicability of WHO classification on a cohort of Pakistani myelodysplastic syndrome (MDS) patients, and determine their epidemiological and clinico-pathological features. STUDY DESIGN: Case series. PLACE AND DURATION OF STUDY: Haematology Department, Shaikh Zayed Hospital, Lahore, from April 2004 to March 2006. METHODOLOGY: Forty six patients of primary MDS diagnosed by World Health Organization (WHO) criteria were included in the study by nonprobability purposive sampling. The cohort was classified accordingly and the epidemiological, clinical and haematological parametres were assessed. Descriptive statistics were used to describe the data. RESULTS: Forty six patients (28 males and 18 females) of primary MDS were included in the study. The mean age was 46.21 years. According to the WHO classification, 12 cases of refractory anaemia, 24 cases of refractory cytopenia with multi lineage dysplasia, 1 case of refractory cytopenia with multi lineage dysplasia and ring sideroblasts, 3 cases of MDS unclassified and 3 cases each of refractory anaemia with excess of blasts I and II were diagnosed. Symptomatic anaemia was seen in 37 cases and pancytopenia was documented in 33 cases. Dyserythropoiesis affected 41 cases. Grade III reticulosis was seen in 7 cases. ALIP was present in 13 cases. CONCLUSION: MDS presented at a young age. Refractory cytopenia with multi lineage dysplasia was the dominant disease category. Further studies are suggested for identifying the cytogenetic abnormalities and del 5q- category.
Subject(s)
Myelodysplastic Syndromes/blood , Myelodysplastic Syndromes/epidemiology , Adolescent , Adult , Anemia, Refractory, with Excess of Blasts/blood , Anemia, Refractory, with Excess of Blasts/epidemiology , Anemia, Refractory, with Excess of Blasts/pathology , Anemia, Sideroblastic/blood , Anemia, Sideroblastic/epidemiology , Anemia, Sideroblastic/pathology , Child , Cohort Studies , Female , Hemoglobins/analysis , Humans , Leukocytes , Male , Middle Aged , Myelodysplastic Syndromes/pathology , Pakistan/epidemiology , Platelet Count , World Health Organization , Young AdultABSTRACT
OBJECTIVE: To determine the influence of iron metabolism on the prognosis of acute lymphoblastic (ALL) and (AML)myeloblastic leukemia at the different phases of chemotherapy in children after Chоrnobyl accident. MATERIALS AND METHODS: 333 children (295 - ALL, 38 - AML) were examined at the stages of chemotherapy. Thecomparison group included 93 children without leukemia. Acute leukemia variants, patients survival, relapses, thenature of disease (live child or died), iron methabolism (morphometric parameters of erythrocytes, SI, SF, STf, TS),manifestations of dyserythropoiesis, bone marrow sideroblast and patients radiation dose were taken into account. RESULTS: In 295 patients with ALL the following variants of leukemia were established: pro-B-ALL in 23, «common¼type of ALL in 224, pre-B-ALL in 29, T-ALL in 19. Thirty eight patients were diagnosed with AML (11 - M1, 19 - M2,8 - M4). Doses of radiation in patients with AL were (2.78 ± 0.10) mSv and they did not correlate with clinical andhematological parameters, disease variant. Relapse rates and shorter survival were in patients with T-ALL, pro-B-ALLand AML with SF levels > 500 ng/ml (p < 0.05). The amount of children with normochromic-normocytic anemias andmanifestations of dysplasia of erythroid lineage elements was greater in the AML than in ALL. SF content in patientswas elevated during chemotherapy and was lower than the initial one only in the remission period. Transferrin wasreliably overloaded with iron: TS (70.2 ± 2.3) % compared with the control group (32.7 ± 2.1) %. Correlationbetween TS and survival of patients was detected (rs = -0.45). Direct correlation between the number of iron granules in erythrocariocytes and SF level (rs = 0.43) was established, indicating the phenomena of ineffective erythropoiesis. CONCLUSIONS: The negative influence of iron excess in the patients body on the hemopoiesis function, manifestations of ineffective erythropoiesis and the course of acute leukemia in children have been established. Changes inferrokinetic processes in children can be the basis of leukemоgenesis development.
Subject(s)
Anemia, Sideroblastic/blood , Chernobyl Nuclear Accident , Erythropoiesis/radiation effects , Iron/blood , Leukemia, Myeloid, Acute/blood , Precursor Cell Lymphoblastic Leukemia-Lymphoma/blood , Adolescent , Anemia, Sideroblastic/drug therapy , Anemia, Sideroblastic/etiology , Anemia, Sideroblastic/mortality , Antineoplastic Agents/therapeutic use , Bone Marrow/pathology , Bone Marrow/radiation effects , Child , Child, Preschool , Erythroid Cells/pathology , Erythroid Cells/radiation effects , Female , Humans , Leukemia, Myeloid, Acute/drug therapy , Leukemia, Myeloid, Acute/etiology , Leukemia, Myeloid, Acute/mortality , Male , Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy , Precursor Cell Lymphoblastic Leukemia-Lymphoma/etiology , Precursor Cell Lymphoblastic Leukemia-Lymphoma/mortality , Prognosis , Radiation Exposure/adverse effects , Radiation, Ionizing , Recurrence , Remission Induction , Survival Analysis , Transferrin/metabolism , Ukraine/epidemiologyABSTRACT
Inherited sideroblastic anemia comprises several rare anemias due to heterogeneous genetic lesions, all characterized by the presence of ringed sideroblasts in the bone marrow. This morphological aspect reflects abnormal mitochondrial iron utilization by the erythroid precursors. The most common X-linked sideroblastic anemia (XLSA), due to mutations of the first enzyme of the heme synthetic pathway, delta-aminolevulinic acid synthase 2 (ALAS2), has linked heme deficiency to mitochondrial iron accumulation. The identification of other genes, such as adenosine triphosphate (ATP) binding cassette B7 (ABCB7) and glutaredoxin 5 (GLRX5), has strengthened the role of iron sulfur cluster biogenesis in sideroblast formation and revealed a complex interplay between pathways of mitochondrial iron utilization and cytosolic iron sensing by the iron-regulatory proteins (IRPs). As recently occurred with the discovery of the SLC25A38-related sideroblastic anemia, the identification of the genes responsible for as yet uncharacterized forms will provide further insights into mitochondrial iron metabolism of erythroid cells and the pathophysiology of sideroblastic anemia.
Subject(s)
Anemia, Sideroblastic/genetics , Erythroid Cells/metabolism , Iron Overload/genetics , Iron/metabolism , 5-Aminolevulinate Synthetase/genetics , ATP-Binding Cassette Transporters/genetics , Anemia, Sideroblastic/blood , Anemia, Sideroblastic/diagnosis , Anemia, Sideroblastic/physiopathology , Anemia, Sideroblastic/therapy , Combined Modality Therapy , Genetic Predisposition to Disease , Glutaredoxins/genetics , Hemochromatosis Protein , Histocompatibility Antigens Class I/genetics , Humans , Iron Overload/blood , Iron Overload/diagnosis , Iron Overload/physiopathology , Iron Overload/therapy , Membrane Proteins/genetics , Mitochondria/metabolism , Mutation , Pedigree , Phenotype , Treatment OutcomeSubject(s)
5-Aminolevulinate Synthetase/genetics , Anemia, Sideroblastic/genetics , Genetic Diseases, X-Linked/genetics , Mutation, Missense/genetics , Anemia, Sideroblastic/blood , Child , Chromosomes, Human, X/genetics , Erythrocytes , Genetic Diseases, X-Linked/blood , Hemizygote , Heterozygote , Humans , MaleABSTRACT
INTRODUCTION: Myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) is a rare disease in the 2016 revised World Health Organization (WHO) classification. Diagnostic criteria include the following: persistent thrombocytosis (>450 × 109 /L) with clustering of atypical megakaryocytes, refractory anemia, dyserythropoiesis with ring sideroblasts, and the presence of the spliceosome factor 3b subunit (SF3B1) mutation. It is unclear if anemia should be a required criterion for this diagnosis as cases which show all other features of MDS/MPN-RS-T but without anemia exist. METHODS: We searched for borderline cases of MDS/MPN-RS-T in which refractory anemia was absent at diagnosis in two major academic institutes. RESULTS: Three cases without anemia were identified. These cases all showed other classic morphologic and clinical features of MDS/MPN-RS-T, including thrombocytosis, atypical megakaryocytes with clustering, and characteristic SF3B1 and JAK2 V617F mutations. CONCLUSION: Given these findings, the requirement of refractory anemia as a diagnostic criterion for MDS/MPN-RS-T should be re-evaluated. Removal of refractory anemia as a diagnostic criterion would incorporate current borderline cases and extend the spectrum of this disorder.